

December 22, 2021

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: New prescription drug report

To: The Office of the Attorney General of Vermont

Ingenus Pharmaceuticals, LLC hereby submits to the Attorney General of Vermont of the following new prescription drug reporting requirements pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost as of the date of Commercial Availability
Cyclophosphamide 2gm/10ml Injection	50742052110	12/20/2021	\$1465.00

Marketing Plan Description:

Promotion of Cyclophosphamide to physicians or other health professionals will be limited to digital and mail media, and relevant Veterans Medical Center conferences.

Estimated Number of Patients:

Ingenus does not tract number of patients.

Breakthrough Therapy/Priority Review/Acquisition Date:

Cyclophosphamide was not granted breakthrough therapy designation or priority review by the FDA, and it was not an acquired product.

Ingenus believes that this report contains all of the required report elements for a new prescription drug report. Please let us know if any additional information is required.

Sincerely,

Senior Director, Government Programs & Price Reporting